Skip To Main Content

The Deliver-G study

DELIVER-G: Real-world analysis in insulin-naïve adults with T2DM on GLP-1 RA ± OAD(s), intensifying their therapy by starting basal insulin and discontinuing GLP-1 RA, or adding basal insulin to ongoing GLP-1 RA, or initiating a FRC product and discontinuing current GLP-1 RA†1

EASD and ADA recommend the addition of basal insulin for people with T2DM who do not achieve glycemic goals on a GLP-1 RA-based regimen.*2,3
The management of type 2 diabetes (T2D) often requires treatment intensification to achieve optimal glycemic control. The DELIVER-G study explores the real-world outcomes of adding Insulin Glargine 300 U/mL (Gla-300) to GLP-1 receptor agonist (GLP-1RA) therapy in people with type 2 diabetes (PWD2). This study builds on findings from the RESTORE-G real-world study, which examined treatment intensification following GLP-1RA therapy.

Observed in a real-world analysis in insulin-naïve adults with T2DM inadequately controlled on GLP-1 RA +/- OAD(s) (with ≥6 months of follow-up data)1*

Observed in a real-world analysis in insulin-naïve adults with T2DM inadequately controlled on GLP-1 RA +/- OAD(s) (with ≥6 months of follow-up data)1*

Observed in a real-world analysis in insulin-naïve adults with T2DM inadequately controlled on GLP-1 RA +/- OAD(s) (with ≥6 months of follow-up data)1*

icon
  • No significant changes in weight (108,0 vs 108,4 kg) or BMI (35,8 vs 36,1 kg/m2)were seen with addition of Toujeo® to GLP-1RAs (baseline vs follow-up, respectively)
  • However, a 3,9% increase in patients with BMI ≥35 kg/m2 was seen (51,5% vs 55,4%; p=0,046)

Study design

DELIVER-G was a retrospective analysis of 271 patients with type 2 diabetes receiving GLP-1 RA therapy who were insulin-naïve prior to subsequent treatment intensification with Toujeo®. DELIVER-G analysed data from a large US electronic medical record data source (IBM® Explorys).

Study population

Insulin-naïve adult patients (N=271) with T2DM receiving GLP-1 RA therapy ± OAD(s) that was subsequently intensified by adding Toujeo®. A total of 156 (57,6%) patients received daily GLP-1 RA and 115 (42,2%) received weekly GLP-1 RA before treatment intensification; 250 (92,3%) patients were receiving at least one OAD prior to intensification with Toujeo® (the mean number of OADs was two).

*Data were extracted from a US electronic medical record data source (IBM® Explorys). Patients selected for inclusion had ≥12 months’ pre-Toujeo® data and ≥6 months of follow-up data.

**Paired Student’s t-test. Change in HbA1c between baseline and follow-up was assessed using the last value recorded within the 3- to 9-month period following intensification with Toujeo®.

Identified by ICD-9 or ICD-10 codes, or a blood glucose recording ≤70 mmol/L, or the number of hypoglycaemic events in the 6-month baseline period vs the 6-month follow-up period. Incidence of any hypoglycaemia pre- and post-intensification with Toujeo® was 8,49% and 9,59%, respectively (p=0,513). Paired Student’s t-test.

One hypoglycaemia-associated inpatient visit was recorded during the baseline period and none during the follow-up period after intensification with Toujeo®; no hypoglycaemia-associated ED visits were recorded during the baseline period and one during the follow-up period. Incidence of any (8,49% vs 9,59%, p=0,513), and inpatient/ED-associated hypoglycaemia (0,37% vs 0,74%, p=1,000), as well as event rates of any (0,33 vs 0,46 PPPY, p=0,170) and inpatient/ED-associated hypoglycaemia (0,01 vs 0,04 PPPY, p=0,466) were similar before and after addition of Toujeo®. When analysed by baseline GLP-1 RA regimen, incidence of hypoglycaemia increased from baseline to follow-up (3,9% to 8,3%, p=0,02; event rate 0,21 to 0,44 PPPY, p=0,017) for those on daily GLP-1RAs. No significant change was observed for those on weekly GLP-1 RAs.

study-design

MAT-BE-2500004 – v. 1.0 – 01/2025